IMPAKT Breast Cancer Conference Media Alert: Oral presentation abstracts online
The impact of new technologies in the care of patients with breast cancer is at the core of the IMPAKT conference on translational research in breast cancer.
Check oral presentation abstracts (full text) as of Thursday, 8 May 2014 at 10:30 (CEST) http://abstracts.
Metastatic breast cancer and development of new drugs...
- Abstract 12O - Molecular subtype of breast cancer metastases significantly influences patient post-relapse survival. N. Tobin
- Abstract 65O - Generation of mouse models for the identification of new driver pathways of drug resistance in human breast cancer. C. Criscitiello
- Abstract 59O - Targeting CDK4/6 in Her2 positive breast cancer: therapeutic effect, markers, and combination strategies. E. Knudsen
- Abstract 60P - Mechanism of action for combined CDK4/6 and ER inhibition in ER positive breast cancer. M. Koehler
- Abstract 69P - Safety and efficacy of MK-8669 (ridaforolimus) + MK-2206 (AKT inhibitor) in patients with advanced breast cancer with PI3K pathway dependence. S. Gupta
While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored. In this context the Breast International Group (BIG) has just launched AURORA, which will use molecular screening to improve our understanding of metastatic breast cancer and its response or lack of response to available drug therapies. In total 1,300 women and men from about 60 hospitals in 15 European countries are expected to take part in the programme. Over time, BIG hopes to expand the programme well beyond Europe to involve several thousand more patients.
"It is almost unethical that we continue to treat women with metastatic breast cancer when we have so little knowledge of their disease. We now have powerful technologies for investigating the molecular landscape of tumours, and we have an obligation to women to establish AURORA as a large translational research effort that can hopefully lead to more effective treatments in the future." - M. Piccart, Chair of BIG and Director of the Medicine Department of the Institut Jules Bordet, Brussels, Belgium
The AURORA trial will be presented during the session
Saturday, 10 May 2014, 10:45-12:35, Gold Hall
Genomics and the importance of translational research to facilitate the implementation of new discoveries into clinical practice...
- Abstract 13O - Evolutionary patterns of microRNA expression through the course of disease and therapy in recurrent breast cancer. M. Dadiani
- Abstract 20O - Analysis of molecular scores for the prediction of distant recurrence according to body mass index and age at baseline. I. Sestak
- Abstract 21O - A novel methylation signature that reflects intratumoral lymphocyte infiltration in breast cancer and predicts for response to anthracycline treatment. J. Jeschke
Patients with estrogen-receptor (ER) positive breast cancer receive hormonal treatments after surgery, but sometimes chemotherapy is also needed. The Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey investigated on the criteria used to decide about chemotherapy in this patient population. Results show that criteria vary significantly across Europe.
"Data from the MAGIC survey reveal that 55% of responding physicians have adopted genomic tests in their practice but adoption varies strongly across countries. Of those physicians who have not used them, the vast majority indicate that they would like to use genomic tests in clinical practice but report lack of reimbursement, price and lack of availability as the main barriers to usage, suggesting a substantial need for broader use of genomic tests that provide information beyond traditional measures and can help physicians and patients make more informed treatment decisions." - M. Aapro, MAGIC survey Lead Investigator and dean of the Multidisciplinary Oncology Institute, Genolier, Switzerland
The MAGIC survey results will be presented during the
Thursday, 8 May 2014, 17:30-19:00, Gold Foyer
- Abstract 1P - Detection of breast cancer and abnormal mammograms with a rapid point-of-care breath test, M. Phillips
- Abstract 5P - The clinical impact of using the IHC4 Score: our MDT experience in a prospective series of postmenopausal women with ER positive early breast cancer, B.J. Yeo
- Abstract 11P - Optimal duration of cardiac monitoring in metastatic HER2 positive breast cancer patients receiving trastuzumab, K. Chiu
- Abstract 17P - The BRCA cancer gene as a useful predictor for double primary breast and ovarian cancer: A meta-analysis, A. Sattaratnamai
- Abstract 70P - Phase I/IIa study with CNS-targeted liposomal doxorubicin (2B3-101) in patients with brain metastases (BM) from breast cancer (BC) and other brain tumours, P.G. Aftimos
The full conference program is available at http://www.
Around 500 attendees are expected from throughout Europe and the rest of the world.
Registered journalists can access all conference sessions and the IMPAKT Press Room.
Press Room opening hours
Thursday, 8 May 2014 10:00 - 18:00
Friday, 9 May 2014 08:00 - 18:00
Saturday, 10 May 2014 08:00 - 13:00
BIG and ESMO welcome media interested in obtaining information and reporting on cancer issues.
Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
Media representatives are required to observe and abide by the IMPAKT Media Policy. http://www.
To register for the event, please fill out the Complimentary Media Registration Form:
IMPAKT Press Office
C/O ESMO Press Office